The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
The effects of the long‐acting angiotensin–converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure
We assessed blood pressure ( BP ) and heart rate ( HR ) responses in a double‐blind , r and omized study comparing cilazapril , a long‐acting , nonsulfhydryl‐group converting enzyme inhibitor , with placebo in 18 patients with mild to moderate ( sitting diastolic BP , 95 to 114 mm Hg ) essential hypertension .  The BP and HR parameters were evaluated at rest ( casual , 24 hours after administration ) , during treadmill exercise testing ( Bruce protocol ) , and with 24‐hour noninvasive ambulatory BP monitoring . These assessment s were made after a 4‐week drug washout period and after 8 to 12 weeks of therapy . After 8 weeks of therapy with cilazapril ( mean dose 3.6 ± 0.9 mg/day ) , casual BP decreased 19/11 mm Hg ( p < 0.01 ) , whereas placebo  lowered BP by 4/5 mm Hg ( difference not significant ) compared with the baseline period . The casual HR was modestly ( 7 beats/min ) but significantly ( p < 0.05 ) lowered by cilazapril  monotherapy . Exercise BP was reduced by cilazapril ( reduction at peak HR , 23/11 ± 10/5 mm Hg ; p < 0.05 ) , and exercise HR was unchanged . Compared with baseline , the duration of exercise was improved with cilazapril but not with placebo ( 1.0 minute vs − 0.2 minute ; p < 0.05 ) . Twenty‐four‐hour mean , awake , and sleep BPs were reduced with cilazapril with the most impressive reduction occurring during the awake period ( 19/12 mm Hg ; p < 0.01 ) . These data demonstrate  that cilazapril  lowers casual , exercise , and ambulatory BP with a modest but significant improvement in exercise time . Thus cilazapril may be particularly effective in the physically active hypertensive patient
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .